Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 17/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 15/20 | 0.60 |
| ▸ | MBTD1 | Q05BQ5 | 6/20 | 0.59 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.59 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23997109 | 0.98 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL17146588 | 0.91 | KDM4E (0.58) | L3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL21959470 | 0.90 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL20682537 | 0.90 | KDM4E (0.54) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL23997048 | 0.89 | KDM4E (0.53) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL22040925 | 0.88 | HPGD (0.65) | L3MBTL1ALDH1A1 | |
| SCHEMBL21959468 | 0.86 | KDM4E (0.55) | L3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL22040920 | 0.85 | HPGD (0.61) | L3MBTL1ALDH1A1 | |
| SCHEMBL20094151 | 0.84 | L3MBTL3 (0.64) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL21958455 | 0.84 | HSP90AA1 (0.51) | L3MBTL3L3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | CAMK1, CAMKK2, DCLK2 | L3MBTL3 3411/4885L3MBTL1 2821/4885MBTD1 2505/4885 |
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | CAMK1, CAMKK2, DCLK2 | L3MBTL3 3411/4885L3MBTL1 2821/4885MBTD1 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.